Genome-edited universal CD7 CAR T cells, autologous nanobody-based CD7 CAR T cells and naturally selected CD7 CAR T cells also showed early efficacy in patients with T-ALL, while CD7-negative relapses were also observed in these studies [16, 24–26]. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.